Company’s 36-month beta value is -2.67.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SLNO is 41.77M, and currently, short sellers hold a 9.55% ratio of that floaft. The average trading volume of SLNO on June 13, 2025 was 1.33M shares.
SLNO) stock’s latest price update
Soleno Therapeutics Inc (NASDAQ: SLNO) has experienced a rise in its stock price by 1.33 compared to its previous closing price of 79.15. However, the company has seen a gain of 6.62% in its stock price over the last five trading days. globenewswire.com reported 2025-05-22 that REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Soleno’s Marketing Authorization Application (MAA) seeking regulatory approval of Diazoxide Choline Prolonged-Release Tablets (previously referred to as DCCR) for the treatment of adults and children four years and older with Prader-Willi syndrome (PWS) who have hyperphagia had been validated by the European Medicines Agency (EMA).
SLNO’s Market Performance
SLNO’s stock has risen by 6.62% in the past week, with a monthly rise of 7.74% and a quarterly rise of 63.57%. The volatility ratio for the week is 1.70% while the volatility levels for the last 30 days are 1.96% for Soleno Therapeutics Inc The simple moving average for the last 20 days is 5.28% for SLNO’s stock, with a simple moving average of 42.96% for the last 200 days.
Analysts’ Opinion of SLNO
Many brokerage firms have already submitted their reports for SLNO stocks, with Stifel repeating the rating for SLNO by listing it as a “Buy.” The predicted price for SLNO in the upcoming period, according to Stifel is $74 based on the research report published on March 05, 2025 of the current year 2025.
Stifel, on the other hand, stated in their research note that they expect to see SLNO reach a price target of $74. The rating they have provided for SLNO stocks is “Buy” according to the report published on December 02nd, 2024.
Robert W. Baird gave a rating of “Outperform” to SLNO, setting the target price at $72 in the report published on December 02nd of the previous year.
SLNO Trading at 9.10% from the 50-Day Moving Average
After a stumble in the market that brought SLNO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -0.98% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SLNO starting from Hirano Patricia C, who sale 3,782 shares at the price of $70.11 back on Apr 01 ’25. After this action, Hirano Patricia C now owns 27,036 shares of Soleno Therapeutics Inc, valued at $265,156 using the latest closing price.
PATRICIA HIRANO, the Officer of Soleno Therapeutics Inc, proposed sale 3,782 shares at $70.11 during a trade that took place back on Apr 01 ’25, which means that PATRICIA HIRANO is holding shares at $265,156 based on the most recent closing price.
Stock Fundamentals for SLNO
The total capital return value is set at -0.54. Equity return is now at value -105.54, with -81.42 for asset returns.
Based on Soleno Therapeutics Inc (SLNO), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -30.2. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is 143.86.
Currently, EBITDA for the company is -173.63 million with net debt to EBITDA at 0.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.64.
Conclusion
In a nutshell, Soleno Therapeutics Inc (SLNO) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
